Two Independent Peer-Reviewed Studies Validate Cernostics’ TissueCypher® Barrett’s Esophagus Assay (TissueCypher®) to Accurately Predict Progression to Esophageal Cancer in Patients with Barrett’s Esophagus

SpaT Study confirms TissueCypher®’s ability to identify non-dysplastic Barrett’s Esophagus (NDBE) patients at high risk for progression to cancer who are missed by current standard of care. These “at-risk” NDBE patients progressed at a highe... Read more
Customer Service

Mon-Fri 9am-5pm (EST)